uniQure NV(QURE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

QURE uniQure NV

Trading 05-06 13:45:07 EDT

22.71

+1.55

+7.33%

High23.15	Low20.50	Vol1.72M
Open20.97	D1 Closing21.16	Amplitude12.50%
Mkt Cap1.43B	Tradable Cap1.13B	Total Shares63.03M
T/O37.79M	T/O Rate3.46%	Tradable Shares49.72M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"QURE","market":"US","secType":"STK","nameCN":"uniQure NV","latestPrice":22.71,"timestamp":1778089500059,"preClose":21.16,"halted":0,"volume":1722902,"delay":0,"changeRate":0.07325141776937621,"floatShares":49724600,"shares":63033249,"eps":-3.46024,"marketStatus":"Trading","change":1.55,"latestTime":"05-06 13:45:07 EDT","open":20.97,"high":23.145,"low":20.5,"amount":37794427.662686,"amplitude":0.125,"askPrice":22.73,"askSize":31,"bidPrice":22.66,"bidSize":1,"shortable":3,"etf":0,"ttmEps":-3.46024,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1778097600000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1391576400000,"exchange":"NASDAQ","adjPreClose":21.16,"preHourTrading":{"tag":"盘前","latestPrice":21.18,"preClose":21.16,"latestTime":"09:29 EDT","volume":2699,"amount":57787.082547,"timestamp":1778074199999,"change":0.02,"changeRate":0.000945,"amplitude":0.034972},"postHourTrading":{"tag":"盘后","latestPrice":21,"preClose":21.16,"latestTime":"19:49 EDT","volume":12239,"amount":258401.8551,"timestamp":1778024960168,"change":-0.16,"changeRate":-0.007561,"amplitude":0.007561},"volumeRatio":1.182555,"impliedVol":1.3318,"impliedVolPercentile":0.6175},"requestUrl":"/m/hq/s/QURE","defaultTab":"news","newsList":[{"id":"2633187509","title":"Goldman Sachs Sticks to Its Hold Rating for uniQure (QURE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633187509","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633187509?lang=en_us&edition=fundamental","pubTime":"2026-05-06 19:20","pubTimestamp":1778066421,"startTime":"0","endTime":"0","summary":"In a report released today, Salveen Richter from Goldman Sachs maintained a Hold rating on uniQure, with a price target of $14.00. Richter covers t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/goldman-sachs-sticks-to-its-hold-rating-for-uniqure-qure-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/goldman-sachs-sticks-to-its-hold-rating-for-uniqure-qure-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["QURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633908100","title":"Chardan Capital Remains a Buy on uniQure (QURE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633908100","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633908100?lang=en_us&edition=fundamental","pubTime":"2026-05-06 12:46","pubTimestamp":1778042771,"startTime":"0","endTime":"0","summary":"Chardan Capital analyst Daniil Gataulin reiterated a Buy rating on uniQure yesterday and set a price target of $37.00. According to TipRanks, Gatau...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/chardan-capital-remains-a-buy-on-uniqure-qure-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/chardan-capital-remains-a-buy-on-uniqure-qure-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LU0889565916.HKD","LU0320765992.SGD","LU0109394709.USD","QURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633597350","title":"Analysts’ Top Healthcare Picks: Spyre Therapeutics (SYRE), uniQure (QURE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633597350","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633597350?lang=en_us&edition=fundamental","pubTime":"2026-05-06 06:50","pubTimestamp":1778021410,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Spyre Therapeutics (SYRE) and uniQure (QURE) with bu...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-spyre-therapeutics-syre-uniqure-qure-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-spyre-therapeutics-syre-uniqure-qure-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SYRE","LABU","LU0889565916.HKD","QURE","BK4585","LU0128526141.USD","XBI","BK4139","BK4588","BK4137","LU0109394709.USD","BK4581","LU0320765992.SGD","LU0029874061.USD","HCSG","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633452779","title":"Uniqure NV reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2633452779","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633452779?lang=en_us&edition=fundamental","pubTime":"2026-05-05 21:31","pubTimestamp":1777987905,"startTime":"0","endTime":"0","summary":"Uniqure NV reports results for the quarter ended March 31 - Earnings SummaryUniqure NV QURE.OQ reported a quarterly adjusted loss of 85 cents per share for the quarter ended March 31, lower than the s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nL8N41I1TT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QURE","LU0889565916.HKD","BK4139","LU0320765992.SGD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633991765","title":"Earnings Flash (QURE) UniQure Posts Q1 Net Loss $0.85 a Share, vs. FactSet Est of $0.85 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2633991765","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633991765?lang=en_us&edition=fundamental","pubTime":"2026-05-05 19:35","pubTimestamp":1777980952,"startTime":"0","endTime":"0","summary":"Earnings Flash (QURE) UniQure Posts Q1 Net Loss $0.85 a Share, vs. FactSet Est of $0.85 Loss","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["QURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633914738","title":"uniQure Q1 EPS $(0.85), Inline, Sales $3.562M Miss $5.223M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2633914738","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633914738?lang=en_us&edition=fundamental","pubTime":"2026-05-05 19:06","pubTimestamp":1777979168,"startTime":"0","endTime":"0","summary":"uniQure (NASDAQ:QURE) reported quarterly losses of $(0.85) per share which met the analyst consensus estimate. This is a 3.66 percent decrease over losses of $(0.82) per share from the same period last year.  The company","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52276558/uniqure-q1-eps-0-85-inline-sales-3-562m-miss-5-223m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QURE","BK4139","LU0889565916.HKD","LU0320765992.SGD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633914703","title":"uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2633914703","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633914703?lang=en_us&edition=fundamental","pubTime":"2026-05-05 19:05","pubTimestamp":1777979100,"startTime":"0","endTime":"0","summary":"~ Advancing FDA interactions on AMT-130 for Huntington’s disease; Type B meeting scheduled for the second quarter of 2026 ~ ~ Progressing AMT-130 toward expected UK regulatory submission; MAA on track","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/05/3287519/0/en/uniQure-Announces-First-Quarter-2026-Financial-Results-and-Provides-Recent-Company-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4215","MAA","LU0889565916.HKD","BK4585","LU0320765992.SGD","LU0109394709.USD","BK4233","UK","BK4205","BK4528","BK4139","QURE","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632983456","title":"A Look At uniQure (QURE) Valuation After AMT-130 Regulatory Progress With The MHRA","url":"https://stock-news.laohu8.com/highlight/detail?id=2632983456","media":"Simply Wall St.","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632983456?lang=en_us&edition=fundamental","pubTime":"2026-05-04 02:16","pubTimestamp":1777832184,"startTime":"0","endTime":"0","summary":"Why AMT-130’s MHRA Meeting Matters for uniQure Stock\nuniQure (QURE) has moved a step further along the regulatory path for AMT-130 in Huntington’s disease after a Pre-Submission Meeting with the UK’s Medicines and Healthcare products Regulatory Agency.\nThe company now plans to file a Marketing Authorization Application in the third quarter of 2026, using three year Phase I/II data that reported a 75% slowing of disease progression at the high dose, with a generally well tolerated and...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qure/uniqure/news/a-look-at-uniqure-qure-valuation-after-amt-130-regulatory-pr","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qure/uniqure/news/a-look-at-uniqure-qure-valuation-after-amt-130-regulatory-pr","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4097","PRGS","BK4585","LU0889565916.HKD","LU2065732104.USD","QURE","LU0109394709.USD","BK4219","LU0320765992.SGD","BK4588","BK4581","BK4084","BK4534","BK4139","BK4554","AMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632769807","title":"uniQure Is Maintained at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2632769807","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632769807?lang=en_us&edition=fundamental","pubTime":"2026-05-01 07:53","pubTimestamp":1777593180,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/QURE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 30, 2026 19:53 ET (23:53 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QURE","BK4139","LU0889565916.HKD","LU0109394709.USD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632481667","title":"uniQure price target raised to $37 from $31 at Chardan","url":"https://stock-news.laohu8.com/highlight/detail?id=2632481667","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632481667?lang=en_us&edition=fundamental","pubTime":"2026-05-01 06:15","pubTimestamp":1777587349,"startTime":"0","endTime":"0","summary":"Chardan raised the firm’s price target on uniQure (QURE) to $37 from $31 and keeps a Buy rating on the shares. The firm cites the company announcem...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/uniqure-price-target-raised-to-37-from-31-at-chardan-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/uniqure-price-target-raised-to-37-from-31-at-chardan-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0109394709.USD","BK4139","QURE","LU0320765992.SGD","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632668671","title":"Update: UniQure Shares Rise After Firm Plans to Submit UK Marketing Application for Huntington's Disease Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2632668671","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632668671?lang=en_us&edition=fundamental","pubTime":"2026-05-01 02:51","pubTimestamp":1777575103,"startTime":"0","endTime":"0","summary":"UniQure  shares were up over 18% in Thursday trading after the company said it plans to submit a UK marketing authorization application in Q3 for AMT-130 for the treatment of Huntington's disease.The plan came after a pre-submission meeting with the UK's Medicines and Healthcare products Regulatory Agency, it said.The company said it has also been granted a Type B meeting with the US Food and Drug Administration in Q2, and expects to discuss key elements of a potential phase III trial design.The company said it is pursuing additional regulatory pathways in international markets for the potential registration of AMT-130 and expects to provide further updates in H2.Price: 19.82, Change: +3.09, Percent Change: +18.47","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0320765992.SGD","QURE","LU0109394709.USD","BK4139","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631763656","title":"uniQure expects UK MHRA filing for AMT-130 in Huntington’s disease in Q3 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2631763656","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631763656?lang=en_us&edition=fundamental","pubTime":"2026-04-30 19:12","pubTimestamp":1777547538,"startTime":"0","endTime":"0","summary":"uniQure secured constructive UK MHRA feedback in pre-submission meeting for AMT-130 Huntington’s disease gene therapy.UK Marketing Authorization Application filing targeted for Q3 2026.U.S. FDA granted Type B meeting in Q2 2026 to review potential Phase III design plus four-year analysis plan.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nNDL8bhq6D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","NDAQ","BK4588","SG9999014005.SGD","LU2095319765.USD","IE00BKPKM429.USD","SG9999014039.USD","LU2210149790.SGD","IE00BGHQF748.EUR","QURE","LU2210150020.SGD","IE00B3QW5Z07.USD","LU0320765992.SGD","LU0109394709.USD","BK4139","LU0889565916.HKD","IE00BN0W2W23.USD","BK4585","BK4112","LU0314104364.USD","SG9999014021.USD","IE00B64PRP62.GBP","SG9999014013.SGD","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631592706","title":"uniQure (QURE) Receives a Buy from H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2631592706","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631592706?lang=en_us&edition=fundamental","pubTime":"2026-04-29 18:36","pubTimestamp":1777459016,"startTime":"0","endTime":"0","summary":"In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on uniQure, with a price target of $70.00. According to T...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/uniqure-qure-receives-a-buy-from-h-c-wainwright-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/uniqure-qure-receives-a-buy-from-h-c-wainwright-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["QURE","LU0889565916.HKD","LU0320765992.SGD","BK4139","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182148467","title":"Earning Preview: uniQure NV Q1 revenue is expected to decrease by 16.75%, and institutional views are cautious","url":"https://stock-news.laohu8.com/highlight/detail?id=1182148467","media":"Earnings Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182148467?lang=en_us&edition=fundamental","pubTime":"2026-04-29 02:33","pubTimestamp":1777401211,"startTime":"0","endTime":"0","summary":"Abstract uniQure NV will report first-quarter 2026 results on May 5, 2026 Pre-Market; investors will watch revenue durability from licensing and collaboration streams, earnings trajectory, and...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Earning Preview: uniQure NV Q1 revenue is expected to decrease by 16.75%, and institutional views are cautious","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630306808","title":"uniQure to Announce First Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2630306808","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630306808?lang=en_us&edition=fundamental","pubTime":"2026-04-28 19:05","pubTimestamp":1777374300,"startTime":"0","endTime":"0","summary":"~ uniQure to host earnings call on Tuesday, May 5, 2026 at 8:30 a.m. ET ~ LEXINGTON, Mass. and AMSTERDAM, April  28, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy compan","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/28/3282448/0/en/uniQure-to-Announce-First-Quarter-2026-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","BK4139","QURE","LU0889565916.HKD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628789365","title":"uniQure call volume above normal and directionally bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=2628789365","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628789365?lang=en_us&edition=fundamental","pubTime":"2026-04-18 02:45","pubTimestamp":1776451516,"startTime":"0","endTime":"0","summary":"Bullish option flow detected in uniQure (QURE) with 4,415 calls trading, 1.5x expected, and implied vol increasing almost 7 points to 157.70%. May-...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/uniqure-call-volume-above-normal-and-directionally-bullish-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/uniqure-call-volume-above-normal-and-directionally-bullish-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["QURE","BK4139","LU0889565916.HKD","LU0109394709.USD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626891114","title":"uniQure put volume heavy and directionally bearish","url":"https://stock-news.laohu8.com/highlight/detail?id=2626891114","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626891114?lang=en_us&edition=fundamental","pubTime":"2026-04-11 00:35","pubTimestamp":1775838919,"startTime":"0","endTime":"0","summary":"Bearish flow noted in uniQure (QURE) with 5,627 puts trading, or 9x expected. Most active are Apr-26 15 puts and Apr-26 16 calls, with total volume...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/uniqure-put-volume-heavy-and-directionally-bearish-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/uniqure-put-volume-heavy-and-directionally-bearish-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0889565916.HKD","LU0109394709.USD","BK4139","LU0320765992.SGD","QURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625676928","title":"uniQure put volume heavy and directionally bearish","url":"https://stock-news.laohu8.com/highlight/detail?id=2625676928","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625676928?lang=en_us&edition=fundamental","pubTime":"2026-04-08 23:15","pubTimestamp":1775661314,"startTime":"0","endTime":"0","summary":"Bearish flow noted in uniQure (QURE) with 1,015 puts trading, or 2x expected. Most active are Apr-26 15 puts and May-26 15 puts, with total volume ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/uniqure-put-volume-heavy-and-directionally-bearish-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/uniqure-put-volume-heavy-and-directionally-bearish-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0320765992.SGD","QURE","LU0109394709.USD","LU0889565916.HKD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625194628","title":"uniQure (QURE) Faces FDA Rebuke, Lawsuits Over AMT-130 Disclosures Is Its Credibility at Risk?","url":"https://stock-news.laohu8.com/highlight/detail?id=2625194628","media":"Simply Wall St.","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625194628?lang=en_us&edition=fundamental","pubTime":"2026-04-06 04:12","pubTimestamp":1775419930,"startTime":"0","endTime":"0","summary":"In recent weeks, uniQure has come under pressure as the FDA publicly rebuked its disclosures around AMT-130’s pivotal study design, prompting multiple securities class action lawsuits alleging misleading statements about regulatory interactions and Biologics License Application timelines.\nThese disputes cut to the core of uniQure’s credibility on its lead Huntington’s disease gene therapy, raising questions about how accurately management has portrayed the program’s regulatory path to...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qure/uniqure/news/uniqure-qure-faces-fda-rebuke-lawsuits-over-amt-130-disclosu","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qure/uniqure/news/uniqure-qure-faces-fda-rebuke-lawsuits-over-amt-130-disclosu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4219","AMT","LU0109394709.USD","BK4581","BK4139","BK4554","BK4585","BK4534","BK4588","LABU","LU0889565916.HKD","BK4084","QURE","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621704195","title":"uniQure Is Maintained at Equal-Weight by Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2621704195","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621704195?lang=en_us&edition=fundamental","pubTime":"2026-03-23 22:26","pubTimestamp":1774275960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/QURE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 23, 2026 10:26 ET (14:26 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","QURE","BK4139","LU0320765992.SGD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.uniqure.com","stockEarnings":[{"period":"1week","weight":0.1723},{"period":"1month","weight":0.2331},{"period":"3month","weight":-0.206},{"period":"6month","weight":-0.2308},{"period":"1year","weight":0.3317},{"period":"ytd","weight":-0.1158}],"compareEarnings":[{"period":"1week","weight":0.017},{"period":"1month","weight":0.1036},{"period":"3month","weight":0.0548},{"period":"6month","weight":0.0798},{"period":"1year","weight":0.2844},{"period":"ytd","weight":0.0614}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.009035},{"month":2,"riseRate":0.5,"avgChangeRate":0.032875},{"month":3,"riseRate":0.307692,"avgChangeRate":-0.046417},{"month":4,"riseRate":0.461538,"avgChangeRate":0.033828},{"month":5,"riseRate":0.692308,"avgChangeRate":0.044325},{"month":6,"riseRate":0.416667,"avgChangeRate":-0.009437},{"month":7,"riseRate":0.25,"avgChangeRate":0.033059},{"month":8,"riseRate":0.5,"avgChangeRate":0.005984},{"month":9,"riseRate":0.25,"avgChangeRate":0.122705},{"month":10,"riseRate":0.5,"avgChangeRate":0.060394},{"month":11,"riseRate":0.75,"avgChangeRate":0.0616},{"month":12,"riseRate":0.25,"avgChangeRate":0.125134}],"exchange":"NASDAQ","name":"uniQure NV","nameEN":"uniQure NV"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"uniQure NV(QURE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest uniQure NV(QURE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"uniQure NV,QURE,uniQure NV股票,uniQure NV股票老虎,uniQure NV股票老虎国际,uniQure NV行情,uniQure NV股票行情,uniQure NV股价,uniQure NV股市,uniQure NV股票价格,uniQure NV股票交易,uniQure NV股票购买,uniQure NV股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"uniQure NV(QURE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest uniQure NV(QURE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}